Ibrutinib, which is an oral inhibitor of BTK, leads to an inhibition of CLL-cell migration, survival and, most importantly, proliferation [69,70], resulting in high ORR when continuously administered. Here, BTK is linked to B-cell chronic lymphocytic leukemia.